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Cancer therapyIntegrins on both tumor cells and the supporting host stromal cells in bone (osteoclasts, new blood vessels,
inﬂammatory cells, platelets and bone marrow stromal cells) play key roles in enhancing bone metastasis.
Tumor cells localize to speciﬁc tissues through integrin-mediated contacts with extracellular matrix and
stromal cells. Integrin expression and signaling are perturbed in cancer cells, allowing them to “escape” from
cell–cell and cell–matrix tethers, invade, migrate and colonize within new tissues and matrices. Integrin
signaling through αvβ3 and VLA-4 on tumor cells can promote tumor metastasis to and proliferation in the
bonemicroenvironment. Osteoclast (OC) mediated bone resorption is a critical component of bonemetastasis
and can promote tumor growth in bone and αvβ3 integrins are critical to OC function and development.
Tumors in the bone microenvironment can recruit new blood vessel formation, platelets, pro-tumor immune
cells and bone marrow stromal cells that promote tumor growth and invasion in bone. Integrins and their
ligands play critical roles in platelet aggregation (αvβ3 and αIIbβ3), hematopoietic cell mobilization (VLA-4
and osteopontin), neoangiogenesis (αvβ3, αvβ5, α6β4, and β1 integrin) and stromal function (osteopontin
and VLA-4). Integrins are involved in the pathogenesis of bone metastasis at many levels and further study to
deﬁne integrin dysregulation by cancer will yield new therapeutic targets for the prevention and treatment of
bone metastasis.d Cell Biology and Physiology,
f Medicine, 660 S. Euclid Ave,
her).
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The development of bone metastasis is common in many cancers,
occurring in virtually all patients with multiple myeloma, in 65%–75%
of patients with advanced breast and prostate cancers, and in 30%–
40% of patients with lung cancer [1–3]. The consequences of bone
metastases are often devastating and can cause pain, pathologic
55J.G. Schneider et al. / Bone 48 (2011) 54–65fractures, spinal cord and other nerve-compression syndromes and
life-threatening hypercalcemia [4]. Both osteolytic lesions and
osteoblastic bonemetastases are associatedwith increased OC activity
and disrupted bone micro-architecture [5,6]. In the bone microenvi-
ronment, tumor cells secrete soluble factors that promote bone
remodeling resulting in the release of additional bone matrix-bound
growth factors which further activate OCs and osteoblasts (OB) and
promote tumor growth [3,4,7–16]. Anti-resorptive therapy, e.g. with
bisphosphonates or denosumab, signiﬁcantly decreases skeletal
complications of cancer and is a standard of care for patients with
bone metastases [4,8,17–19]. In addition to their effects on bone,
tumors in the bone microenvironment recruit blood vessel formation,
platelets, immune cells and stromal cells that promote tumor growth
and invasion in bone. Integrin-mediated cell signaling plays a critical
role in many of these processes during bone metastasis, including
platelet aggregation (αIIbβ3), hematopoietic/immune cell mobiliza-
tion (VLA-4 and osteopontin), neoangiogenesis (αvβ3, αvβ5, α6β4,
and β1 integrin) and stromal function (osteopontin and VLA-4) (see
Fig. 1). For these reasons, the mechanisms by which integrin signaling
mediates the pathogenesis of bone metastasis have been an area of
active research.
Integrin structure, activation and signaling
Integrins are heterodimeric transmembrane glycoproteins that
facilitate cell–cell and cell–extracellular matrix (ECM) adhesion and
cell migration [20]. Integrins recruit many intracellular signaling
molecules and can activate survival, proliferation, andmotility signaling
pathways [21]. There are 8 beta and 18 alpha integrin subunits that
assemble into 24 unique known combinations in different cell types,
each characterized by distinct ligand binding speciﬁcities (including
collagen, osteopontin, ﬁbronectin, laminin, and others, depending on
the integrin family), signaling abilities, and regulatorymechanisms [22].
Integrins are activated by conformational changes in the integrin
extracellular domains. When the integrin α and β subunit cytoplasmic
and transmembrane domains remain closely juxtaposed, the extracel-
lular domains are held in a closed conformation. Activation by
intracellular signals to the cytoplasmic tails results in separation of the
α and β cytoplasmic and transmembrane domains and exposure of the
extracellular ligand binding domain [23] (inside-out signaling). TheIntegrin Expression Du
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Fig. 1. Integrin Expression During Bone Metastasis: Numerous host stromal cells types inter
Preclinical and clinical evidence demonstrate that speciﬁc integrin expression and signalingopen conformation, facilitates high afﬁnity ligand binding and triggers
integrin-mediated cell signaling cascades (outside-in signaling) [24,25].
Many proteins play critical roles in the activation of speciﬁc
integrins, but two cytoplasmic proteins, talin and kindlin, are
necessary for inside-out signaling required for the activation of all
integrin subtypes [23,26–29]. Talin binds to the proximal end of the
beta cytoplasmic tail via a phosphotyrosine-binding (PTB) domain
within its FERM domain [27] and links the integrin to the actin
cytoskeleton [23]. Kindlin 1, 2, or 3, is necessary for talin-induced
integrin activation [26,30,31]. Kindlin, like talin, also interacts with
intracellular proteins resulting in cytoskeleton reorganization and
adhesion [32]. G-protein coupled receptors such as the ADP receptor
P2Y12, also play critical roles in the inside-out signaling required for
integrin activation [25,33,34]. Structure–function analyses on β3
integrins have shown that a membrane-proximal region is important
for inside-out signaling [28,35–40].
In addition to activation by inside-out signaling, ligand binding
and integrin clustering can be signiﬁcantly modulated by growth
factor receptor interactions and other integrin interacting proteins, as
reviewed in [22,23,41]. For example, integrin associated protein,
CD47, augments integrin activation and affects the ability of αvβ3
integrin to cluster upon ligand binding [42]. Ligation of the integrin
then stimulates outside-in signaling that leads to the activation of
numerous signals critical for growth, migration, survival and other
functions, including FAK phosphorylation, ERK signaling, and NF-κB
activation. Thus, integrin signaling in cancer cells and in associated
stromal, endothelial and hematopoietic cells can be inﬂuenced by
intracellular signaling proteins, growth factors, chemokines and other
receptors that participate in regulating integrin function through
effects on integrin activation, ligand binding, ligand afﬁnity and
integrin clustering.
Maintaining adhesion to the ECM, in part through integrin
signaling, is critical to cell survival [43]. Altered cell–cell or cell–
ECM interactions results in disruption of downstream survival
signaling and anchorage-dependent non-transformed cells undergo
anoikis [43]. Under normal conditions, because each cell type
expresses a unique set of integrins that recognize underlying ECM
ligands, this form of apoptosis ensures that detached cells do not
colonize inappropriate locations [43]. Cells that resist anoikis, such as
metastatic cells, take advantage of several different mechanisms soring Bone Metastasis
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act with tumor cells to facilitate tumor cell homing, colonization and invasion in bone.
on both tumor cells and host cells are central to facilitating bone metastasis.
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expression [44], constitutive activation of molecules usually activated
via integrin signaling including FAK [45], EGFR [46] and SRC [47], and
lack of activation of pro-apoptotic pathways [48], among others.
The integrin family of adhesion receptors links ECM to the
cytoskeleton through a complex and regulated network of activation,
interaction with numerous growth factor, GPCR, chemokine and
cytokine receptors and induction of complex signaling cascades.Integrin expression and signaling on tumor cells that metastasize
to bone
Tumor progression, invasion and eventual metastasis require the
activity of many adhesion proteins, including the integrin superfam-
ily. At each stage of cancer progression, subsets of integrin hetero-
dimers are activated, providing the necessary signaling pathways for
adhesion, migration and cell survival. Metastatic tumor cells show
differential integrin heterodimerization and activation compared to
non-metastatic tumor cells that enable the cell to home to and
colonize in a metastatic site, such as the bone marrow cavity [49,50].
In order for primary epithelial cancers to metastasize, the tumor cells
must become resistant to anoikis and detach from the primary tumor
site ECM, enter the vasculature, and eventually colonize a distant site.
Upon reaching a successful metastatic site, however, tumor cells use
both anoikis and anoikis-resistance to their advantage, in some cases
forming micro-metastases that are resistant to cancer treatment via
integrin binding to the underlying bone ECM as reviewed in [51].
Tumor cells must also form interactions between the tumor cell and
bone stroma to establish and maintain skeletal metastasis. Many
integrins have been implicated in tumor cell–host bone stroma
interactions during bonemetastasis and tumor growth in bone (Fig. 1,
Table 1), including the β1 and β3 integrin family members.
avβ3 is a receptor for osteopontin, ﬁbronectin, and vitronectin,
ECM proteins that are important bone matrix proteins, and αvβ3 has
been identiﬁed as a critical integrin in breast cancer and prostate
cancer skeletal metastasis [50,52–56]. Interestingly, although αvβ3
has been shown to bind to ﬁbronectin in other locations with high
afﬁnity, tumorαvβ3 integrins do not bind ﬁbronectin in bonemarrow
stroma, indicating that αvβ3-expressing tumor cells bind to the bone
stromal ligands vitronectin and osteopontin [57]. In breast cancer,
αvβ3 binding of host osteopontin is necessary for tumor cell
colonization to bone [58]. Bone metastatic cells have a higher
expression of αvβ3 than the primary tumor [53], promoting
adherence to the bone matrix by binding osteopontin expressed by
bone stromal cells [58]. Breast cancer cells that overexpress αvβ3
have increased levels of bonemetastasis and associated tumor burden
and osteolysis [52,59–62]. This overexpression of αvβ3 in the tumor
cells leads to increased tumor cell adhesion, migration and invasion to
bone as well as enhanced OC recruitment within the bone microen-Table 1
Extracellular matrix proteins and the main integrins that participate in bone metastasis
and tumor growth in bone.
Integrin ECM ligands
αvβ3 Vitronectin, osteopontin, bone sialoprotein, ﬁbronectin, TSP-1
α2β1 Collagen I, laminin
α4β1 (VLA-4) VCAM-1 ﬁbronectin, osteopontin
αvβ1 Fibronectin, vitronectin
αvβ5 Vitronectin, osteonectin, bone sialoprotein, ﬁbronectin
αIIbβ3 Fibrinogen
β2 VCAM-1, ICAM-1, ﬁbrinogen
α1β1 Collagen
α5β1 Fibronectin
α9β1 TSP1
α6β4 Laminin, TSP-1vironment [60,61], implicating a role of tumor-speciﬁc αvβ3
expression in breast cancer metastasis to bone as well as tumor-
associated osteolysis. Likewise, in prostate cancer cells, active αvβ3 is
necessary for the adherence and migration to bone matrix proteins at
early stages of skeletal metastasis. This tumor cell αvβ3 integrin
expression allows cancer cells to adhere to the bone matrix and
interact directly with the native bone cells, OBs and OCs, as well as
with the bone matrix itself [59].
The β1 family member, α5β1, has been identiﬁed as the primary
integrin receptor for ﬁbronectin on human bone marrow stroma [57].
α5β1 expression on leukemia, prostate and breast cancer cells
facilitates interaction with bone stroma [57,63–65]. Antibody inhibi-
tion of α5, β1 or ﬁbronectin blocks prostate cancer tumor cell binding
to bone stroma, indicating necessary roles for both integrin α5β1 on
tumor cells and ﬁbronectin on bone marrow stromal cells [57]. In
breast cancer skeletal metastasis, the interaction between malignant
cell α5β1 and host stromal cell ﬁbronectin contributes to the survival
of growth-arrested tumor cells, a potential mechanism throughwhich
tumor cells can become sequestered and “dormant” within the bone
marrow cavity andmay later begin to proliferate to establish a skeletal
metastasis [64]. Upon FGF-2 growth factor stimulation, breast cancer
cells undergo growth arrest and up-regulateα5β1 expression. Inmost
cases, these cells die, but cells that bind ﬁbronectin via α5β1 and
initiate cell survival signaling cascades survive [64].
Another β1 family member, α2β1, a collagen type I receptor, is
expressed by prostate tumor cells, and its activity promotes invasion
and adherence to the bone stroma. The presence of collagen I, the
most abundant protein in bone, signiﬁcantly increases prostate
epithelial cell adhesion in culture, and antibody inhibition of integrin
subunits α2 and β1 signiﬁcantly inhibits tumor cell binding to stroma
[66]. Hall et al. showed that a skeletal metastatic prostate cancer cell
line, but not cell lines that are metastatic to other organs, binds to
collagen I and that this collagen I binding is α2β1 dependent in vivo
[67]. Interestingly, stromal expression of collagen I does not increase
tumor growth, but instead promotes tumor cell migration [67]. Tumor
cell α2β1 binding of host bone marrow stromal collagen I activates
RhoC GTPase which instigates a signaling cascade responsible for
cytoskeleton reorganization, migration, and, eventually, collagen-
stimulated invasion and preferential skeletal metastasis [68].
α4β1/vascular cell adhesion molecule-1 (VCAM-1) binding has
been identiﬁed as important for cell–cell contact between α4β1
expressing myeloma cells and VCAM-1 expressing bone marrow
stroma [69]. This interaction contributes to bone tumor growth, OC
stimulation and resultant osteolysis [69,70]. Likewise, epithelial
tumor cells (CHO) that overexpress α4β1 developed signiﬁcantly
more bone metastases than mice inoculated with CHO cells alone
[71]. Bone metastases, but not other metastases, were inhibited by
antibodies against α4 and/or VCAM-1, suggesting a role for α4β1/
VCAM-1 binding in the skeletal metastases of solid tumors [71].
The role of integrins and chemokine cross talk in tumor cell
homing to bone will be discussed later. While many aspects of
tumor–bone stromal interactions remain unknown, it is clear that
speciﬁc interactions between tumor cell integrins and bone stromal
cell ligands are essential for successful homing and metastasis to
bone.
Integrin expression and signaling in osteoclast function and bone
metastasis
Bone invading metastatic tumor cells co-opt integrin signaling
pathways that enhance OC function and recruitment. As part of
bone remodeling, OCs bind to the bone matrix, form an actin ring
mediated sealing zone, secrete enzymes and acid to degrade bone,
and then migrate to a new site. Each of these functions is regulated
in part by integrins located on the membrane surface of the OC,
interacting with neighboring cells and with the ECM [72].
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αvβ3 (osteopontin, vitronectin, bone sialoprotein), αvβ5 (ﬁbronec-
tin), and α2β1 (collagen) [73,74]. Of these, αvβ3 is the predominant
integrin found on OCs, and antibody inhibition of αvβ3 inhibits OC
attachment to the bone matrix as well as OC mediated bone
resorption [75]. In addition, mice with targeted disruption of β3
integrin (β3−/−) have defective OC function [76] and are protected
from tumor-associated osteolysis [77]. αvβ3 is responsible for
mediating OC-bone recognition [53,75,78,79] and subsequent attach-
ment to the bone matrix [75,80], signaling to create the characteristic
resorptive rufﬂed membrane, regulation of OC spreading, and overall
organization of the cytoskeleton [76,81]. Activation of αvβ3 regulates
OC adhesion and migration on osteopontin, important for OC
polarization and bone resorption [82]. Osteopontin ligand binding of
αvβ3 causes a reduction of OC cytosolic calcium, inducing podosome
formation and subsequent resorption [83]. In addition,αvβ3 is critical
for the activation of c-Src, c-Cbl, and GTPases Rho and Rac, signaling
that is necessary for the cytoskeletal reorganization important in OC
function [81,84,85].
OC targeted therapy is a standard of care for the treatment of
bone metastasis and myeloma bone disease. Tumor cells recruit OCs
resulting in bone destruction and pain [3,86,87]. Because of its
known role in OC function and its high expression in skeletal
metastatic tumors much research has focused on αvβ3 integrin and
its ligands. An important characteristic of αvβ3 mediated cell
adhesion, both in OCs and tumor cells, is the requirement of
osteopontin, an αvβ3 ligand [58]. Osteopontin is a non-collagenous
bone matrix protein that is produced by OBs, OCs, and macrophages
and is found in the ECM adjacent to calciﬁed bone [88–90].
Expression of osteopontin in both the tumor cell and in the bone
microenvironment can promote skeletal metastasis [91,92]. Osteo-
pontin-deﬁcient mice have reduced bone metastasis and tumor-
induced osteolysis than wild type controls in a mouse model of
tumor metastasis using syngeneic B16 melanoma cells [93,94],
conﬁrming a role for host cell osteopontin expression during bone
metastasis. Recombinant osteopontin induces cell migration of B16
cells that is inhibited by repressing the ERK/MAPK pathway,
suggesting that the ERK/MAPK pathway regulates bone microenvi-
ronment osteopontin levels [91]. Overexpression of osteopontin in
B16 melanoma cells increases cell proliferation and migration,
indicating that the ligand also plays an important role in the tumor
cell itself [91]. It has been demonstrated using a prostate cancer cell
line overexpressing osteopontin that tumor cell osteopontin
regulates MMP-9 secretion and the subsequent CD44/MMP-9
interaction, important for the migration of prostate cancer cells,
contributing to metastatic potential [95]. Osteopontin-producing
tumor cells enhance osteopontin production by OBs [96] and OCs
[97], stimulating osteoclastogenesis, OC adherence, migration, and
bone resorption via host αvβ3 binding [88,98]. Osteopontin
activation of αvβ3 integrin leads to downstream activation of
FAK, c-Src kinase, and Ras-ERK, among other signaling molecules,
resulting in cytoskeletal reorganization, focal adhesion formation,
basolateral membrane differentiation, and osteoclastic resorption
[59,99].
CD47, integrin associated protein, is expressed constitutively
and interacts with integrins, including αvβ3, as part of inside-out
signaling cascades and also operates in an integrin-independent
manner. CD47 plays a role in OC and macrophage biology and
CD47−/− mice have decreased OC number and function [100,101]
which can be rescued in vitro by inhibiting nitric oxide synthase
[101]. CD47−/− mice have decreased bone metastases and tumor-
associated osteolysis compared to wild type [101]. During the early
stages of osteoclastogenesis, namely, macrophage fusion, CD47
binds with SIRP1α, a molecule that is transiently induced in
myeloid cells and that likely participates in early fusion events
[102]. In the event of tumor cell metastasis to bone, however, ithas been reported that cancer cells may utilize this macrophage
self-recognition signaling to fuse with macrophages [103], leading
to mature OCs with tumor cell nuclei and subsequent over-
expression of OC stimulation factors, thus leading to increased OC
function [104].
These data underscore the importance of integrins, especially
αvβ3, and its adaptor proteins in OC biology and bone metabolism
and point to the role of OC integrins in regulating growth of cancer
cells in the bone.
Integrins and tumor neovasculature and bone metastasis
Tumor neovascularization is essential for tumor cell invasion and
metastasis. Access to the host blood supply provides the tumor cells
with nutrients and connects the tumor to the circulation, facilitating the
dissemination of metastatic cells. The angiogenic process begins with
the de-stabilization and de-differentiation of local vessels, followed by
activation of endothelial cells (EC), EC migration and proliferation into
the tumor ECM, and ﬁnally organization of ECs into functional vessels.
The ability of tumor cells to activate the normally quiescent vasculature
is proposed to be controlled by an “angiogenic switch” mechanism,
whereby tumor or stromal cells induce changes in the relative balanceof
inducers (e.g. vascular endothelial growth factor (VEGF) or TGFβ, PDGF,
TNFα, bFGF) and inhibitors (e.g. thrombospondin-1 [TSP-1]) of
angiogenesis reviewed in [41,105–109]. Activated platelets, tumor
cells, andﬁbroblasts secretemany of these pro-angiogenic factors. It has
recently been appreciated thatmacrophage lineage cells play important
roles in promoting tumor-associated angiogenesis [110–113]. Bone
metastasis and bone residing tumors like myeloma also modify and
recruit ECs to enhance neoangiogenesis [114,115].
Many integrin heterodimers have been implicated in tumor-
associated angiogenesis [41,105–109,116]. The ﬁrst integrin found to
regulate angiogenesis, αvβ3, is expressed at high levels on tumor-
associated vasculature [117,118] and tumor-associated angiogenesis
can be inhibited by β3 integrin neutralizing antibodies [119–122].
αvβ3 has been speciﬁcally implicated in the angiogenesis associated
with prostate cancer bone metastases; antibody inhibition of αvβ3
decreases tumor-associated blood vessels in mice [123]. Interestingly,
Reynolds et al. demonstrated enhanced (not reduced) tumor-
associated angiogenesis in subcutaneous tumors in β3−/− mice
[124]. Elevated levels of VEGFR2 were found on tumor-associated
blood vessels in β3−/−mice, and a VEGFR2 inhibitor could block the
enhanced blood vessel formation [125]. It should be noted that an
inhibitor of integrin binding and signaling might have different
consequences than loss of integrin expression. For example, apoptotic
machinery is activated in certain cells expressing integrins that are
not ligand-bound [126–129]. Recent reports that low dose integrin
antagonists can increase tumor growth and angiogenesis while higher
doses suppress tumor growth and angiogenesis [130] underscore the
complexity of targeting β3 integrins for angiogenesis and cancer
therapy.
Another αv integrin, αvβ5, also shows increased expression on
tumor-associated vasculature, and αvβ5 antibodies inhibit VEGF-
induced tumor-associated angiogenesis [131]. In contrast, the β3/
β5−/− double knockout mice show enhanced tumor-associated
angiogenesis, as was seen in β3−/− mice [125]. Several hypoth-
eses have been proposed that reconcile the contradictory results
involving the αv integrin family that outline the roles of the
integrins as pro-angiogenic, anti-angiogenic, and/or working
through different pathways as reviewed in [41,108]. It is clear,
however, that αvβ3 and αvβ5 have distinct roles in regulation of
tumor-associated angiogenesis and associated metastasis. The bone
targeted bisphosphonate, zoledronic acid, alters EC integrin-
mediated adhesion by reduced expression of αvβ3 and αvβ5
integrin on ECs in vitro in one observation [132]. This observation
provides a possible mechanism for OC-independent anti-tumor
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models [133–135] and clinically [136–139]. Evaluation of the
effects of bisphosphonates on integrin signaling in the tumor–
bone microenvironment is underway.
While much of the research in integrin-mediated angiogenesis has
been focused on the αv integrins, there is evidence that other
heterodimers play a role in angiogenic regulation, particularly the β1
and β4 families. The β1 integrin family (α1β1, α2β1, α5β1, and
α4β1) has a critical role in angiogenesis with β1−/− mice having
severe vascular defects. α1β1 (a collagen receptor) and α2β1 (a
laminin receptor) have been shown to be important for mediating cell
adhesion in VEGF-stimulated ECs [140]. In vivo, function-blocking
antibodies to α1 and α2 signiﬁcantly inhibited VEGF-induced
angiogenesis, indicating a positive regulatory role for α1β1 and
α2β1 expression in tumor-associated angiogenesis [141]. Genetic
data further support a role for the integrin α1β1 as a positive
regulator of angiogenesis as α1-deﬁcient mice show reduced
angiogenesis [142].
Fibronectin receptor α5β1 has also been implicated as a positive
regulator of angiogenesis: α5β1 antagonists inhibit tumor-associated
angiogenesis in mice by inhibition of EC migration and regulating
proliferation and apoptosis [143,144]. Importantly, the α5β1 antago-
nists did not inhibit angiogenesis induced by VEGF, indicating that the
integrin α5β1 (together with αvβ3) may act in a VEGF-independent
pathway [144]. α4β1, together with its ligand, VCAM-1, expressed in
vessel mural cells, plays an important role in adhesion of ECs and
vascular smooth muscle cells during blood vessel formation [145].
Both anti-α4β1 antibodies and anti-VCAM-1 antibodies inhibit
angiogenesis in vivo. Another integrin, laminin receptor α6β4 is
reported to regulate several aspects of tumor angiogenesis. Genetic
studies revealed that α6β4 promotes endothelial cell migration in
culture; in addition, the integrin is involved in the translational
regulation of VEGF, having a pro-angiogenic effect [146,147].
In many cases, integrins inﬂuence angiogenesis through their
interaction with the integrin ligand thrombospondin 1 (TSP-1). Mice
with a TSP-1 deﬁciency have increased tumor burden and tumor-
associated vasculature, both in capillary size and number, while mice
that overexpress TSP-1 have delayed or absent tumor growth and
reduced tumor-associated vasculature [148]. These data indicate that
TSP-1 can contribute to tumor burden via negative regulation of
angiogenesis. In contrast, in a human breast cancer cell line, TSP-1
stimulation up-regulates both integrin subunit α6 mRNA levels and
protein levels which leads to increased adhesion to ECM protein
laminin in vitro, suggesting that TSP-1 facilitates pathogenic angio-
genesis [149]. TSP-1 also interacts with α9β1 via its N-terminal
domain and has a positive effect on proliferation and motility in
culture and on angiogenesis in vivo that can be reduced by α9β1
inhibitors. This binding of the microvasculature-associated integrin in
ECs with TSP-1 activates signaling cascades including ERK and
paxillin. Thus, TSP-1 can play both pro- and anti-angiogenic roles,
depending on its speciﬁc integrin interaction.
The roles of integrins in tumor-associated angiogenesis are
complex, not only involving integrin ligand interactions and associ-
ated signaling pathways, but also speciﬁc temporal regulation and
indirect effects through proteins such as TSP-1, and are important for
the progression of angiogenesis and eventual metastasis.
Integrin-hematopoietic cell interactions: tumor-induced
mobilization and modulation of bone marrow cells
The bone marrow is the primary site of hematopoiesis in the adult.
OBs and bone marrow stromal cells regulate hematopoietic stem cell
(HSC) growth, differentiation and bone marrow retention through
numerous signaling pathways including integrin VLA-4/VCAM [150],
chemokine SDF-1/CXCR4, BMPs and Notch [151–156]. Hematopoietic
progenitors and stem cells express the integrin VLA-4 and thechemokine receptor CXCR4. OB and bone marrow stromal cells
produce VCAM-1, SDF-1 and osteopontin, all important components
of the “HSC niche” [157–159]. Integrin and chemokine signaling work
in concert to promote HSC and progenitor cell homing and
mobilization in the bone marrow [160]. Disruption of VLA-4/VCAM-
1 and SDF-1/CXCR4 interactions results inmobilization of HSC into the
circulation [159]. G-CSF mobilization of HSC acts in part through
disruption of VLA-4/VCAM-1 and CXCR4/SDF1 interactions [158,161].
OC resorption can also regulate HSC mobilization and the stem cell
niche [162].
Diverse integrins are expressed on hematopoietic progenitor cells
in speciﬁc patterns and at distinct time points [163]. Integrins not only
mediate the binding of normal progenitor cells to stroma and matrix
molecules, but may also regulate expansion, maturation and differ-
entiation of those cells [164,165]. For example, α4β1 integrin
regulates hematopoietic progenitor cell fate through changes in
integrin expression and activity levels during cell maturation and
differentiation into erythrocytes and neutrophils [165–167]. α4
containing integrins mediate adhesion of hematopoietic progenitors
to stromal cells likely through binding to matrix components such as
ﬁbronectin [168] or cellular receptors such as VCAM-1 [169]. The
integrin subunits α5, α6 and α9 have also been shown to be
expressed by progenitor cells [170–172]. Studies using blocking
antibodies demonstrated that α6 subunit cooperates in collaboration
with theα4 subunit in regulating the homing of progenitor cells [171].
α9β1 integrin is also important for adhesion of progenitor cells to OBs
in the bone marrow [172], illustrating the fact that hematopoiesis
takes place in three dimensional matrices, the so-called bone marrow
niches. These niches are located at the endosteum near OBs and in the
vascular niche close to marrow blood vessels [173].
Tumor cells both in the bone microenvironment and at distant sites
canmodulate andmobilize hematopoietic progenitor and immune cells
to promote bone and visceral metastasis and local tumor growth.
Tumor-induced mobilization of VEGFR+ and Sca+kit-bone marrow
derived cells has been implicated in enhancing distant tumor and
metastatic growth [174]. These mobilized VEGFR+ cells also express
α4β1 and can migrate to sites of increased synthesis of matrix
components such as ﬁbronectin and establish a “pre-metastatic niche”
that can favor tumormetastasis and growth [174]. β2 integrins on bone
marrow derived endothelial progenitors can also mediate the adhesion
and VEGF-induced migration of the progenitors to the mature
endothelium of actively remodeling vasculature [175].
Tumor cells from a primary lesion can act at a distance to inﬂuence
bone marrow hematopoiesis through secreted factors such as the
integrin ligand, osteopontin [176]. Primary epithelial tumors can
instigate growth of indolent tumors through modulation of the bone
marrowmicroenvironment andmobilization and recruitment of bone
marrow cells to distant tumor sites [176,177]. McAllister et al. found
that tumor secretion of osteopontin is necessary but not sufﬁcient in
xenograft models to modulate the bone microenvironment and
promote bone marrow cell recruitment to tumor metastasis [176].
Pazolli et al. found that osteopontin secreted by senescent ﬁbroblasts
promoted tumorigenesis in animal models of skin cancer [178].
Thus tumors cells both in bone and at distant sites can modulate
hematopoiesis in part through osteopontin and bone marrow cell
integrins resulting in the mobilization and recruitment of bone
marrow derived cells that will enhance local and metastatic tumor
growth.
Integrins and tumor cell homing/colonization of bone
The site of metastasis is tumor cell speciﬁc depending on their
integrin, chemokine receptor and cytokine/receptor expression
proﬁles [50,179–181]. At the metastatic site, normal physiology is
changed towards increased secretion of cytokines and activation of
integrins to support recruitment, survival and growth of tumor cells.
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physiological hematopoietic progenitor cell homing to bone through
expression of integrins and chemokines [150,152,153]. CXCR4
expressed on cancer cells can direct those cells to bone [181–186].
The migration of myeloma cells to and across bone marrow stromal
cells is in part regulated by SDF-1α/CXCR4 ligation and up-regulation
of α4β1 (VLA-4) results in adhesion of myeloma cells to the
underlying bone marrow stroma [187]. Likewise, CXCR4 ligation can
increase αvβ3 expression and aggressiveness of metastatic prostate
cancer cells, and disruption of CXCR4 can inhibit prostate cancer bone
metastases [183–185].
It has recently been shown that β3 integrin activity on circulating
CXCR4-positive bone marrow derived cells is important for their
migration and recruitment to sites of angiogenesis. In mice with
mutated tyrosine residues “knocked in” to the β3 integrin locus to
inhibit proper phosphorylation (DiYF mice) [188], CXCR4-positive
bone marrow derived cells were higher in number and defective in
recruitment to subcutaneously implanted tumors or wounds, where
SDF-1 levels were also lower [189]. These data demonstrate that β3
integrin on bone marrow derived cells may be critical for the CXCR4/
SDF-1 gradient, and thus may be important for localization of tumor
cells to the bone microenvironment and also localization of myeloid/
ECs to tumors. Interestingly, CXCR4 deletion on bonemarrow cells can
enhance OC activity which could counteract some of the beneﬁcial
effects of CXCR4 inhibition on bone metastases [9].
Integrins expressed by tumor cells, in concert with bone
microenvironment chemokine secretion and further integrin activa-
tion, determine the osteotropic characteristics of metastasizing cancer
cells and represent an ideal target for skeletal metastatic cancer
therapy.
Integrins and myeloid/immune cell function during tumor
growth in bone
Myeloid cell integrins are involved in tumor escape from immune
responses and tumor-induced angiogenesis. Bone marrow derived
myeloid cells (macrophages, monocytes, myeloid derived suppressor
cells, andmyeloid dendritic cells) migrate to tumors and contribute to
tumor growth, invasion and angiogenesis [190–194]. Macrophages
within tumors, called tumor-associated-macrophages (TAM) [127],
are recruited by chemoattractants such as MCP-1 [195] secreted by
the tumor and then differentiate into tissue macrophages [196]. The
anti-tumor M1 phenotype represents a classical activation that is
induced by pathogens, lipopolysaccharides (LPS) or interferon gamma
resulting in secretion of proinﬂammatory cytokines such as tumor
necrosis factor α (TNFα), interleukin 1β (IL-1 β) and others. M1
macrophages can act in an anti-tumor fashion by secretion of
cytotoxic cytokines and antigen presentation to lymphocytes [197].
The pro-tumor M2 phenotype, represents alternative activation
induced by IL-4 or IL-10 [198]. M2 polarized macrophages promote
tumor cell proliferation and survival, suppress immune responses and
drive tumor neoangiogenesis [197,199–201]. Studies have shown that
the TAM content of tumors and prognosis of patients are inversely
correlated [192,202,203].
β2 integrins are involved in monocyte/myeloid cell migration
through endothelium and in phagocytosis, while β1 integrins mediate
adhesion to matrix proteins and the induction of inﬂammatory genes
[204]. α4β1 and αvβ3 integrins have been implicated in myeloid cell
homing, adhesion and migration to tumors. α4β1 promotes endo-
thelial progenitor cells and monocyte homing and adhesion to sites of
active pathological angiogenesis [205]. Inhibition of α4β1 leads to
suppressed monocyte and macrophage colonization of tumors and
associated vasculature and decreased angiogenesis [194].
The αvβ3 integrin is down-regulated during differentiation of bone
marrow myeloid progenitor cells to monocytes but induced in
macrophages during inﬂammation [206,207]. αvβ3 promotes myeloidhoming, adhesion and migration of bone marrow derived cells through
the endothelium to sites of tumor angiogenesis [189]. β3 integrins are
involved in phagocytosis of apoptotic cells [208,209] and limit the
secretion of inﬂammatory mediators [207]. Defective macrophage
tumor inﬁltration is observed in TAM from β3−/− bone marrow,
myeloid speciﬁc β3KOM−/− mice and in the signaling defective DiYF
β3mice (micewith twomutated tyrosine residues) [111,189,210–213],
suggesting that defective cytoskeletal reorganization or lack of
appropriately polarized macrophages [212] within tumors may be due
to β3 integrin deﬁciency.
Myeloid derived suppressor cells (MDSC) [214] represent a
subpopulation of immature myeloid cells that are roughly character-
ized by GR1+ and by the αMβ2(CD11b) integrin adhesion marker
[214]. The MDSC suppress T-cell antigen receptor mediated immune
responses [190] and can promote TAM M2 polarization [215]. MDSC
from myeloma bearing mice had a greater capacity to become bone
resorbing cells compared toMDSC from control mice [191]. The role of
integrins in MDSC differentiation, recruitment and function is under
investigation. Integrins are involved in monocyte/macrophage differ-
entiation and recruitment to tumors and can inﬂuence local and
metastatic tumor growth.
Integrins and tumor recruited platelets and bone metastasis
Cancer cells co-exist with platelets and mononuclear hematopoi-
etic cells in thrombi located throughout the organs of patients with
metastatic cancer [216–218]. Platelet aggregation and activation
enhances tumor growth and metastasis to bone [77,219]. Platelets
are anuclear metabolically active cells that are formed from bone
marrowmegakaryocytes. Platelet aggregation is stimulated by soluble
factors such as ADP and thromboxane (TXA2), membrane proteins,
collagen or von Willebrand factor that are produced by injured
endothelial, inﬂammatory and tumor cells. αIIbβ3 plays a central role
in the initiation of arterial thrombosis and platelet aggregation
[220,221]. αIIbβ3 integrins are expressed on the surface of mega-
karyocytes and platelets and are undetectable on any other non-
cancerous cell type. Mice globally deﬁcient for the β3 integrin have
prolonged bleeding times, defects in platelet aggregation and clot
retraction and cutaneous and gastrointestinal bleeding, all character-
istics of Glanzmann's thrombasthenia, [222] a disease characterized by
functional reduction or absence of αIIbβ3 in humans. Targeting β3
integrins by monoclonal antibodies to the receptor (abciximab/
Reopro) or by inhibiting the binding of the ligand ﬁbrinogen to the
receptor (tiroﬁban/Integrilin) are used in patientswith acute coronary
and cerebral vascular syndromes but have signiﬁcant bleeding risks
that prevent their usefulness for chronic uses such as cancer.
Tumor cell lines have been shown to induce platelet aggregation
and adhesion in vitro through mechanisms involving αIIbβ3 integrin,
ADP, thrombin, vonWillebrand factor and selectins [77,223–229]. The
metastatic potential of tumor cell lines is markedly diminished in
mice with defective platelet aggregation (β3 integrin−/−, Gaq−/−,
Par4−/−, NFE2−/− and ﬁbrinogen−/−) [77,219,223,226,228–244].
β3−/− mice are protected from bone metastasis in part through a
mechanism involving defective platelet aggregation [77]. Additional-
ly, tumor cells engineered to respond to platelet-derived lysopho-
sphatidic acid (LPA) have enhanced bone metastatic potential in mice
[219]. Platelets also represent a signiﬁcant source of pro-angiogenic
(VEGF) and anti-angiogenic factors (TSP-1) and are recruited to tumor
sites where their aggregation could affect local tumor growth [245].
Platelet-speciﬁc integrin targeting is a promising therapeutic ap-
proach for inhibiting bone metastasis, especially to prevent or slow
metastasis.
In contrast to platelets, bone marrow megakaryocytes can inhibit
prostate cancer tumor growth in bone [246]. Megakaryocytes can
indirectly inhibit bone resorption by inhibiting OC formation [247].
The negative effect of megakaryocytes on bone resorption is likely
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is contained in secretory granules of platelets and megakaryocytes
[248,249]. Adhesion of mature polyploid megakaryocytes to ﬁbro-
nectin is also mediated by β1 subunit containing integrins [250,251].
Megakaryocytes may also inﬂuence bone remodeling and resorption
through effects on OB proliferation that are mediated by the α3β1,
α5β1 and glycoprotein IIb integrins [252]. Given the location of
maturemegakaryocytes at vascular sinusoids, they are also among the
ﬁrst cells to physically encounter cancer cells as they enter the bone
marrow, so a direct mechanism of action involving integrin-mediated
signal transduction could be involved. Interestingly, bisphosphonates
(BP) increase megakaryocyte proliferation and increase the platelet
concentration of the anti-angiogenic integrin ligand TSP-1 [253–255]
which suggests non-OC mechanisms of BPs' action in decreasing
tumor growth in bone. Thus, platelets and their megakaryocytic
precursors interact with cancer cells before, during and after
metastasis to bone through interactions mainly determined by
integrins and their ligands.Integrins and bone metastasis: Therapeutic aspects
Because of the wide range of functions in physiological and
pathological processes, the integrin family of adhesion receptors has
been adopted as a promising target for metastatic bone diseases.
Several tumor cell types express an abnormal integrin proﬁle
compared to non-tumor cells [41,51,256], providing an opportunity
for speciﬁc targeting. Targeting integrins on both tumor and/or host
cells has proven to be effective not only in blocking local cancer
progression, but also in reducing tumor cell detachment from their
primary site in preclinical models [257–259].
In recent years, integrins on the tumor cells and the endothelium
have been targeted by monoclonal antibodies and RGD peptides in
order to reduce tumor angiogenesis [109,260]. Integrin antagonists,
including humanized monoclonal antibodies, small molecule antago-
nists and cyclic peptides, have been developed based on the
recognition sequences of integrin physiological ligands [261]. Several
compounds are already in clinical use or undergoing their clinical
evaluation for various diseases.
For the future treatment of skeletal metastasis, the αvβ3 integrin
has become an attractive target because of its expression in tumor and
angiogenic cells, its role in OC differentiation and function and its role
in tumor cell homing to bone [53,60,61,183,262–267]. The multiple
expected beneﬁcial effects on endothelial, cancer and osteoclastic
cells instigated a signiﬁcant effort to develop drug candidates that
target the αvβ3 integrin for therapy of skeletal complications of
cancer. These strategies resulted predominantly in antagonists of
αvβ3, αvβ5 and αIIβ3 integrins that showed efﬁcacy in animal
models. Peptidomimentic antagonists of theαvβ3 andαvβ5 integrins
were successfully used to inhibit OC in vitro and to reduce bone loss in
a rat osteoporosis model [268]. An active nonpeptide αvβ3 integrin
antagonist and anti-αvβ3 antibodies were shown to hinder cancer
induced bone loss [79,268–270]. It is possible that the current
treatment for bone metastasis, BPs, may also exert an effect on
αvβ3 on both ECs [132] as well as OCs in a similar manner.
Many drugs candidates targeting integrin αvβ3 have advanced to
the clinic for the treatment of osteoporosis and cancer, though none
have speciﬁcally targeted patients with bone metastases. A lipophilic
isoester of RGD (L000845704), developed by Merck, is effective in
increasing bone mineral density (BMD) in postmenopausal women
[271]. Another inhibitor, RGD-mimetic cyclic peptide Cilengitide
(EMD-1219974) directed at both αvβ3 and αvβ5 [272] and currently
investigated by MerckSerono, is in advanced stages of clinical testing
for the treatment of glioblastoma multiforme and is under investiga-
tion for the treatment of squamous cell carcinoma, prostate cancer,
and lung cancer (Phase II).Clinical trials of function-blocking antibodies are also ongoing,
including Vitaxin (LM609), a humanized monoclonal IgG1 antibody
against the extracellular domain of the αvβ3 integrin heterodimer.
Vitaxin had substantial anti-angiogenic effects in preclinical models
[119,262] and has shown direct anti-tumor effects as well as impaired
bone resorption by inhibiting OC attachment to the bone surface
[273]. Another monoclonal antibody (CNTO95), directed against the
αv subunit, is under development by Centocor and is in phases I–II
testing for solid tumors. Two other additions to this therapeutic family
are planned to be more speciﬁcally evaluated for their effects on bone
metastasis [62], organic small molecule GLPG0187 [62] and peptide
antagonist S247 [257].
Given the participation of the OCs, blood vessels and platelets in
bone metastases, it may be beneﬁcial to block both αvβ3 and αIIβ3
integrins on host cells. This concept of combination inhibition relies
on the common RGD ligand binding domains of αvβ3, αvβ5 and
αIIbβ3. In fact, many of the synthetically designed αvβ3 integrin
inhibitors display some selectivity towards αvβ5 integrin, and, in
the case of Cilengitide, this dual antagonism is part of the
mechanism to treat cancer by inhibiting neoangiogenesis as well
as invasion [274,275]. The strategy to combine multiple targets also
bears some risks with regards to the desired high therapeutic
speciﬁcity and low off-target toxicity. This issue is further
complicated by the differential function of the integrins as
determined by their location, expression level, activation status
and ligand binding. Studies in animal models and xenograft tumor
models have demonstrated that low concentrations of αvβ3
integrin antagonists can act as integrin agonists [130,276,277].
Further research is necessary to identify optimal drug dosing and
targeting that overcome the problem of generalized integrin
inhibition to reduce or prevent skeletal metastasis.
Another area of active research in bone metastasis therapeutics
is the speciﬁc targeting of integrins on HSCs or progenitors that
prepare the metastatic niche and enhance bone marrow coloniza-
tion by cancer cells which then instigate the vicious cycle of bone
metastasis [278,279]. Interfering with integrin-mediated homing of
cancer cells to the cells to the bone represents an early option for
intervention. siRNA against the αv integrin subunit was used to
prevent the progression of prostate cancer to bone by interfering
with the ECM–integrin interaction [280]. In another approach, a
disintegrin and a neutralizing antibody to VCAM-1 or its receptor
α4β1 integrin reduced metastasis of melanoma cells and dimin-
ished osteolysis by decreasing OC activity in a myeloma in vitro
model [69,281]. These strategies, however, are not yet in clinical
trials. An exciting new approach to cancer therapy takes advantage
of the fact that cancer cells use CXCR4 and VLA-4 to home to and
engraft in the marrow. HSC mobilizing agents such as AMD3100 and
anti-VLA-4 targeted agents can be used to mobilize leukemia and
myeloma cells into the blood from the bone marrow leading to
increased sensitivity to chemotherapy [282–284] in mice. This
approach is now being tested in clinical trials.
Future perspectives
Despite the high level of complexity of the integrin family, the
β3 integrin remains a major target in the search for effective
therapies for skeletal metastasis. In recent years, a steady increase
in knowledge has led to clinical testing of several interesting
compounds. There remains, however, a lack of clarity concerning
the exact roles of the integrins in different cell types. In the initiated
clinical studies using αvβ3 integrin antagonists, the overall effect in
reducing tumor growth and pathological angiogenesis in fast
progressing deadly tumors may outweigh potential undesired
effects in tissues or cells other than tumor or endothelial origin.
Drugs designed to tackle skeletal complications of cancer must be
targeted to the bone microenvironment. This fact is underscored by
61J.G. Schneider et al. / Bone 48 (2011) 54–65the clinical successes of the bone matrix targeted bisphosphonates
and the OC targeted denosumab in treating and preventing skeletal
complications of bone metastases and myeloma. A detailed
understanding of the role of integrin regulation in both the
metastatic tumor cells and the tumor-associated stroma will allow
for a more targeted and focused approach to treat bone metastases.
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